Dinutuximab  (Synonyms: 地努图希单抗; APN-311)

Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer^[1][2][3].

ganglioside GD2

Dinutuximab (0-5000 ng/mL; 0-12 天) 可抑制乳腺癌细胞 MDA-MB-231 粘附、迁移、乳腺球形成，诱导细胞凋亡，以及抑制 mTOR、ERK 和 4E-BP1 的磷酸化^[1]。
Dinutuximab (100 ng/mL; 6-72 小时) 在人神经母细胞瘤细胞系 SH-SY5Y-Fluc、CHLA-136-Fluc 和 CHLA-255-Fluc 中，与体外激活的自然杀伤细胞 (aNK) 联合使用时，显著降低肿瘤细胞的活力和侵袭能力^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Dinutuximab (15 μg; 尾静脉注射; 每周两次; 4 周) 在小鼠神经母细胞瘤模型中具有抗肿瘤的活性^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2583  [NCBI]

Q00973

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.012 kDa

地努图希单抗; APN-311

1363687-32-4

液体

Colorless to light yellow

地努图希单抗；地努妥昔单抗；地妥西单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Ly S, et al. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. J Immunother Cancer. 2021 Mar;9(3):e001197.  [Content Brief]

  [2]. Barry WE, et al. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma. Clin Cancer Res. 2019 Jan 1;25(1):325-333.  [Content Brief]

  [3]. Ploessl C, et al. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma. Ann Pharmacother. 2016 May;50(5):416-22.  [Content Brief]